New strategies in the development of anti-atherosclerotic drugs

C. R. Sirtori, E. Tremoli, R. Paoletti

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The results of several recently completed trials of cardiovascular prevention, by the use of hypolipidemic or anti-platelet compounds, have suggested that new strategies be followed for the development of anti-atherosclerotic drugs. The final outcome of preventive studies with hypolipidemic compounds is markedly influenced by the significance of the achieved hypolipidemia, as well as by the side-effects, some of which, i.e. lithogenicity, may be related to the drugs' mechanism of action. Significant differences may, moreover, exist between the findings in animal models and in humans, particularly by clofibrate and related compounds. The evaluation of drugs active on lipoprotein biosynthesis in the gut (metformin), potent enzyme inhibitors (compactin) and with chelating activity (cetaben), is awaited with interest. In the field of drugs affecting platelets, a selective sensitivity for the major compounds in different vascular areas has been observed. Aspirin appears to be mostly effective in cerebro-vascular prevention. Agents affecting the thrombin-platelet coagulation interaction, i.e. GYKI 14,451, may offer an interesting opportunity for testing the importance of this pathway in clinical thrombosis.

Original languageEnglish
Pages (from-to)507-518
Number of pages12
JournalArtery
Volume8
Issue number6
Publication statusPublished - 1980

Fingerprint

tert-butyloxycarbonyl-phenylalanyl-prolyl-arginal
Blood Platelets
Blood Vessels
Pharmaceutical Preparations
Clofibrate
Drug Evaluation
Critical Pathways
Metformin
Enzyme Inhibitors
Thrombin
Aspirin
Lipoproteins
Thrombosis
Animal Models
Outcome Assessment (Health Care)
cetaben
mevastatin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Sirtori, C. R., Tremoli, E., & Paoletti, R. (1980). New strategies in the development of anti-atherosclerotic drugs. Artery, 8(6), 507-518.

New strategies in the development of anti-atherosclerotic drugs. / Sirtori, C. R.; Tremoli, E.; Paoletti, R.

In: Artery, Vol. 8, No. 6, 1980, p. 507-518.

Research output: Contribution to journalArticle

Sirtori, CR, Tremoli, E & Paoletti, R 1980, 'New strategies in the development of anti-atherosclerotic drugs', Artery, vol. 8, no. 6, pp. 507-518.
Sirtori, C. R. ; Tremoli, E. ; Paoletti, R. / New strategies in the development of anti-atherosclerotic drugs. In: Artery. 1980 ; Vol. 8, No. 6. pp. 507-518.
@article{d4e376b382e4488c8c0241a9a0695958,
title = "New strategies in the development of anti-atherosclerotic drugs",
abstract = "The results of several recently completed trials of cardiovascular prevention, by the use of hypolipidemic or anti-platelet compounds, have suggested that new strategies be followed for the development of anti-atherosclerotic drugs. The final outcome of preventive studies with hypolipidemic compounds is markedly influenced by the significance of the achieved hypolipidemia, as well as by the side-effects, some of which, i.e. lithogenicity, may be related to the drugs' mechanism of action. Significant differences may, moreover, exist between the findings in animal models and in humans, particularly by clofibrate and related compounds. The evaluation of drugs active on lipoprotein biosynthesis in the gut (metformin), potent enzyme inhibitors (compactin) and with chelating activity (cetaben), is awaited with interest. In the field of drugs affecting platelets, a selective sensitivity for the major compounds in different vascular areas has been observed. Aspirin appears to be mostly effective in cerebro-vascular prevention. Agents affecting the thrombin-platelet coagulation interaction, i.e. GYKI 14,451, may offer an interesting opportunity for testing the importance of this pathway in clinical thrombosis.",
author = "Sirtori, {C. R.} and E. Tremoli and R. Paoletti",
year = "1980",
language = "English",
volume = "8",
pages = "507--518",
journal = "Artery",
issn = "0098-6127",
number = "6",

}

TY - JOUR

T1 - New strategies in the development of anti-atherosclerotic drugs

AU - Sirtori, C. R.

AU - Tremoli, E.

AU - Paoletti, R.

PY - 1980

Y1 - 1980

N2 - The results of several recently completed trials of cardiovascular prevention, by the use of hypolipidemic or anti-platelet compounds, have suggested that new strategies be followed for the development of anti-atherosclerotic drugs. The final outcome of preventive studies with hypolipidemic compounds is markedly influenced by the significance of the achieved hypolipidemia, as well as by the side-effects, some of which, i.e. lithogenicity, may be related to the drugs' mechanism of action. Significant differences may, moreover, exist between the findings in animal models and in humans, particularly by clofibrate and related compounds. The evaluation of drugs active on lipoprotein biosynthesis in the gut (metformin), potent enzyme inhibitors (compactin) and with chelating activity (cetaben), is awaited with interest. In the field of drugs affecting platelets, a selective sensitivity for the major compounds in different vascular areas has been observed. Aspirin appears to be mostly effective in cerebro-vascular prevention. Agents affecting the thrombin-platelet coagulation interaction, i.e. GYKI 14,451, may offer an interesting opportunity for testing the importance of this pathway in clinical thrombosis.

AB - The results of several recently completed trials of cardiovascular prevention, by the use of hypolipidemic or anti-platelet compounds, have suggested that new strategies be followed for the development of anti-atherosclerotic drugs. The final outcome of preventive studies with hypolipidemic compounds is markedly influenced by the significance of the achieved hypolipidemia, as well as by the side-effects, some of which, i.e. lithogenicity, may be related to the drugs' mechanism of action. Significant differences may, moreover, exist between the findings in animal models and in humans, particularly by clofibrate and related compounds. The evaluation of drugs active on lipoprotein biosynthesis in the gut (metformin), potent enzyme inhibitors (compactin) and with chelating activity (cetaben), is awaited with interest. In the field of drugs affecting platelets, a selective sensitivity for the major compounds in different vascular areas has been observed. Aspirin appears to be mostly effective in cerebro-vascular prevention. Agents affecting the thrombin-platelet coagulation interaction, i.e. GYKI 14,451, may offer an interesting opportunity for testing the importance of this pathway in clinical thrombosis.

UR - http://www.scopus.com/inward/record.url?scp=0019300959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019300959&partnerID=8YFLogxK

M3 - Article

C2 - 7020650

AN - SCOPUS:0019300959

VL - 8

SP - 507

EP - 518

JO - Artery

JF - Artery

SN - 0098-6127

IS - 6

ER -